- Home
- BIRK vs ASND Comparison
BIRK vs ASND Comparison
Compare BIRK & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | ASND |
|---|---|---|
| Founded | 1774 | 2006 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 13.6B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BIRK | ASND |
|---|---|---|
| Price | $34.65 | $220.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $62.69 | ★ $279.50 |
| AVG Volume (30 Days) | ★ 2.0M | 439.8K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.76 | $97.60 |
| Revenue Next Year | $14.29 | $43.64 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.06 | $124.06 |
| 52 Week High | $57.39 | $248.60 |
Technical Indicators
Market Signals| Indicator | BIRK | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 44.45 |
| Support Level | $33.06 | $214.39 |
| Resistance Level | $42.19 | $236.58 |
| Average True Range (ATR) | 1.61 | 8.13 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 36.74 | 30.72 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.